Cellular Therapy

A 68-year-old with AML in first remission is eligible for allogeneic transplant, but the trial that quantified how much conditioning intensity buys him in relapse reduction never enrolled anyone his age.

Post-transplant cyclophosphamide is what made haploidentical transplant survivable in the first place. Whether it should also replace decades of calcineurin-inhibitor practice for a matched sibling donor is a genuinely newer, harder question.

Ruxolitinib has the best randomized evidence for steroid-refractory acute GVHD, but its own trial's myelosuppression signal lands differently in a patient whose marrow only just cleared engraftment.

Choosing a third-line agent for chronic GVHD after ibrutinib failure means weighing which pivotal trial's population actually looks like this patient — and a real drug interaction narrows the choice further.

A durable first remission after autologous transplant is itself evidence about this patient's biology — but it competes against two newer options with a much closer match to her current, triple-class-refractory disease.

Consolidative transplant would address her leukemia's known tendency to relapse early — and would also eliminate the CAR-T cells that are the reason she's in remission today.

Caught early and at low burden, a post-transplant AML relapse doesn't obviously call for the most aggressive available option — but waiting has its own real cost if the gentler approach doesn't hold.

Whether to treat Grade 1 cytokine release syndrome early turns out to matter less than making sure the right drug is reserved for the different syndrome that might follow it.

High disease burden before CAR-T infusion is genuinely associated with worse outcomes — but nobody has proven that debulking it first actually reverses that association, and that gap is the entire debate.

A large, unselected trial found no benefit to a second transplant. A smaller, risk-stratified one found real benefit in exactly her cytogenetic subgroup. Both are true at once.